

Date: 11 March 2022

**Re: Freedom of Information Request**  
**Ref: 70-2022**

Thank you for your email dated the 4/3/2022, requesting information in relation to breast cancer treatment.

The information you require has been provided below:

I am researching the treatment of Triple-Negative (ER negative, PR negative and HER2 negative) breast cancer. Could you please tell me how many patients you have treated for Triple Negative breast cancer in the last 3 months with the following systemic anti-cancer therapies:

- a) Anthracycline (eg doxorubicin) as single agent **0**
- b) Atezolizumab + nab-paclitaxel or paclitaxel **25**
- c) Capecitabine as a single agent **36**
- d) Eribulin as a single agent or in combination **2**
- e) PARP inhibitor (eg Olaparib) **0**
- f) Pembrolizumab + chemotherapy **0**
- g) Platinum (eg carboplatin, cisplatin) as a single agent **4**
- h) Taxane (eg docetaxel, paclitaxel, nab-paclitaxel) as a single agent **243**
- i) Taxane + Anthracycline based combinations **0**
- j) Vinorelbine as a single agent **1**
- k) Other active systemic anti-cancer therapy

Other	Number of patients
AC (Adriamycin and cyclophosphamide)	<b>2</b>
Aspirin/placebo (ADD Aspirin Trial)	<b>18</b>
Atezolizumab	<b>5</b>
Carboplatin 21day + Paclitaxel 7day	<b>168</b>
Cyclophosphamide + Docetaxel	<b>6</b>
Denosumab	<b>31</b>
EC (Epirubicin Cyclophosphamide)	<b>127</b>
GemCarbo Days 1+8	<b>7</b>
LETROZOLE	<b>1</b>

Paclitaxel+Pertuzumab+Trastuz SC	16
Palbociclib	2
Palbociclib + Fulvestrant	3
Phesgo	4
Trastuzumab Subcutaneous	6
Zoladex	11
Zoledronate	122

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

Margaret Moore  
Information Governance Administrator  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)